Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28008252 | 0.87 | NLRP3 (0.50) | TSHRTDP1PIN1LMNASMN1; SMN2 | |
| SCHEMBL28008699 | 0.85 | TSHR (0.46) | TSHRTDP1PIN1LMNASMN1; SMN2 | |
| SCHEMBL31074064 | 0.85 | TSHR (0.53) | TSHRTDP1PIN1LMNASMN1; SMN2 | |
| SCHEMBL10858287 | 0.85 | TSHR (0.53) | TSHRTDP1PIN1LMNASMN1; SMN2 | |
| SCHEMBL7509738 | 0.85 | MMP8 (0.51) | TSHRTDP1PIN1LMNAKMT2A | |
| SCHEMBL31198070 | 0.84 | TDP1 (0.44) | TSHRTDP1PIN1KMT2AMEN1 | |
| SCHEMBL10708969 | 0.84 | CASP1 (0.57) | TSHRPIN1LMNASMN1; SMN2KMT2A | |
| SCHEMBL31257144 | 0.84 | PIN1 (0.47) | TSHRTDP1PIN1LMNASMN1; SMN2 | |
| SCHEMBL16673225 | 0.84 | TDP1 (0.51) | TSHRTDP1PIN1LMNASMN1; SMN2 | |
| SCHEMBL8873528 | 0.84 | PIN1 (0.47) | TSHRTDP1PIN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20220402854-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKENE ETHERS | NEUROBO PHARMACEUTICALS INC (US) | 2022-12-22 | — | — | US | disclosed |
| CN-111057168-B | Catalyst for olefin polymerization and preparation method and application thereof | 中国石油化工股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-09-30 | — | — | US | disclosed |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-09-30 | — | — | US | disclosed |
| CN-112469722-A | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-108112251-B | NRF2 modulators | 葛兰素史克知识产权发展有限公司 | 2021-03-05 | — | — | CN | disclosed |
| CN-111704543-A | Process and intermediates for preparing alpha, omega-dicarboxylic acid terminated dialkyl ethers | 燿石治疗公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-3653598-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING , -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | Gemphire Therapeutics Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20200048181-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | NEUROBO PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20160137584-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | GEMPHIRE THERAPEUTICS INC. | 2016-05-19 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| EP-1781617-A4 | ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-24 | — | — | EP | disclosed |
| EP-1781617-A2 | ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006004742-A2 | α, β-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION | JANSSEN PHARAMCEUTICA N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
| WO-2002030860-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2003-02-20 | — | — | WO | disclosed |
| EP-0383346-B1 | Catalyst, process for its preparation and process for polymerization of olefins using this catalyst | SHOWA DENKO KK (JP) | 1995-05-03 | — | — | EP | disclosed |
| US-5041403-A | Magnesium, titanium, halogen, ester compound, and organic aluminum compound | SHOWA DENKO K.K. (JP) | 1991-08-20 | — | — | US | disclosed |
| EP-0383346-A2 | Catalyst, process for its preparation and process for polymerization of olefins using this catalyst | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1990-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | TSHR 138/4885TDP1 1604/4885PIN1 3688/4885 |
| US-20220402854-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKENE ETHERS | ELOVL3, DGKI, ELOVL5 | TSHR 3793/4885TDP1 3558/4885PIN1 3904/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | TSHR 4825/4885TDP1 1477/4885PIN1 1490/4885 |
| US-20160137584-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING a,w -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | BCKDK, DGKI, DDC | TSHR 3486/4885TDP1 3075/4885PIN1 2906/4885 |
| US-20200048181-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | DGKI, DGKA, SQLE | TSHR 3661/4885TDP1 3260/4885PIN1 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.